NIH Technology Licensing Opportunity: A Novel Lymphatic/Brain Targeting Macromolecular Prodrug System
January 27, 2021 @ 11:00 AM – 12:00 PM
This webinar introduces a novel technology, a polymeric drug delivery platform that targets the lymphatic system and brain through scavenger receptor A1 (SR-A1) mediated transcytosis. The SR-A1 receptor is highly expressed in macrophages, monocytes, mast cells, and dendritic cells (myeloid lineages), and also endothelial cells. The platform can deliver various therapeutic/diagnostic imaging cargo to the to the brain, and to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations for treatment of various disease states or for tracking response to therapy. This lymphatic-targeting polymeric drug delivery system is particularly well suited for delivery of immunomodulatory drugs and delivering cancer therapeutics to the lymphatic environment that metastatic cancer cells use to spread to other parts of the body, including the brain. This lymphatic-targeting polymeric drug delivery platform can also enable diagnostic activities associated with monitoring the lymphatic spread of metastatic cancers and evaluating treatment response.
This is an opportunity to interact with the inventor, ask questions, provide feedback and assess the opportunity to license this technology or participate in a collaboration to further its development.
Stephan T. Stern, Ph.D., DABT
Laboratory Co-Director, Director of Research & Development
Nanotechnology Characterization Laboratory
Frederick National Laboratory for Cancer Research
Joseph M. Conrad III, Ph.D., J.D.
Senior Technology Transfer Manager
Invention Development & Marketing Unit
NATIONAL CANCER INSTITUTE, Technology Transfer Center